These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697 [TBL] [Abstract][Full Text] [Related]
6. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227 [TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge. Liu Q; Zhao H; Li Z; Zhang Z; Huang R; Gu M; Zhuang K; Xiong Q; Chen X; Yu W; Qian S; Zhang Y; Tan X; Zhang M; Yu F; Guo M; Huang Z; Wang X; Xiang W; Wu B; Mei F; Cai K; Zhou L; Zhou L; Wu Y; Yan H; Cao S; Lan K; Chen Y Signal Transduct Target Ther; 2023 Sep; 8(1):347. PubMed ID: 37704615 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™. Guzmán-Bringas OU; Gómez-Castellano KM; González-González E; Salinas-Trujano J; Vázquez-Leyva S; Vallejo-Castillo L; Pérez-Tapia SM; Almagro JC Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902040 [TBL] [Abstract][Full Text] [Related]
10. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM Front Immunol; 2022; 13():871874. PubMed ID: 35898497 [TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188 [TBL] [Abstract][Full Text] [Related]
12. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
13. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271 [TBL] [Abstract][Full Text] [Related]
14. Camel nanobodies broadly neutralize SARS-CoV-2 variants. Hong J; Kwon HJ; Cachau R; Chen CZ; Butay KJ; Duan Z; Li D; Ren H; Liang T; Zhu J; Dandey VP; Martin N; Esposito D; Ortega-Rodriguez U; Xu M; Borgnia MJ; Xie H; Ho M bioRxiv; 2021 Oct; ():. PubMed ID: 34751270 [TBL] [Abstract][Full Text] [Related]
15. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196 [TBL] [Abstract][Full Text] [Related]
16. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination. Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434 [TBL] [Abstract][Full Text] [Related]
17. Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern. Schwarze M; Krizsan A; Brakel A; Pohl F; Volke D; Hoffmann R Front Immunol; 2022; 13():915034. PubMed ID: 35784285 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Tarrés-Freixas F; Trinité B; Pons-Grífols A; Romero-Durana M; Riveira-Muñoz E; Ávila-Nieto C; Pérez M; Garcia-Vidal E; Perez-Zsolt D; Muñoz-Basagoiti J; Raïch-Regué D; Izquierdo-Useros N; Andrés C; Antón A; Pumarola T; Blanco I; Noguera-Julián M; Guallar V; Lepore R; Valencia A; Urrea V; Vergara-Alert J; Clotet B; Ballana E; Carrillo J; Segalés J; Blanco J Front Microbiol; 2022; 13():840757. PubMed ID: 35602059 [TBL] [Abstract][Full Text] [Related]
19. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. Wang X; Hu A; Chen X; Zhang Y; Yu F; Yue S; Li A; Zhang J; Pan Z; Yang Y; Lin Y; Gao L; Zhou J; Zhao J; Li F; Shi Y; Huang F; Yang X; Peng Y; Tu L; Zhang H; Zheng H; He J; Zhang H; Xu L; Huang Q; Zhu Y; Deng K; Ye L Signal Transduct Target Ther; 2022 Apr; 7(1):114. PubMed ID: 35383141 [TBL] [Abstract][Full Text] [Related]
20. Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs. Lee J; Kim B; Woo HM; Kim JW; Jung I; Park SW; Kim YS; Na JH; Jung ST Mol Pharm; 2024 Jul; ():. PubMed ID: 39058261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]